AI assistant
Sending…
EyePoint Pharmaceuticals, Inc. — Director's Dealing 2023
Jun 22, 2023
32254_dirs_2023-06-22_6195b9ce-42d8-4013-8b1f-7c1f19ae39a7.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: EyePoint Pharmaceuticals, Inc. (EYPT)
CIK: 0001314102
Period of Report: 2023-06-20
Reporting Person: Duker Jay S. (N/A)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2023-06-20 | Restricted Stock Units | $0.00 | A | 62380.00 | Acquired | Common Stock (62380.00) | Direct |
Footnotes
F1: The restricted stock units will vest in three ratable annual installments beginning January 6, 2024.
More from EyePoint Pharmaceuticals, Inc.
Regulatory Filings
2026
May 14
Regulatory Filings
2026
May 6
Investor Presentation
2026
Apr 13
Director's Dealing
2026
Mar 24
Legal Proceedings Report
2026
Mar 20
Regulatory Filings
2026
Mar 4
Regulatory Filings
2026
Mar 2
Director's Dealing
2026
Feb 18
Major Shareholding Notification
2026
Feb 12
Director's Dealing
2026
Jan 7